By Morgan Conley ( November 17, 2021, 7:57 PM EST) -- The maker of a drug for pediatric patients with a rare autoimmune disease told the Eleventh Circuit it must reconsider a panel ruling in favor of its rival Catalyst Pharmaceuticals Inc. en banc, arguing the panel "constructed a straw man" that misconstrues what was really in dispute....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.